Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and...

Area of Science:

• Endocrinology and Metabolism
• Plastic Surgery

Background:

• Obesity is a significant public health issue in the United States.
• Injectable medications, primarily glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide, are increasingly used for weight management.
• These drugs, including Ozempic, Wegovy, Saxenda, and Mounjaro, are widely discussed on social media, leading to noticeable physical changes.

Purpose of the Study:

• To inform plastic surgeons about the growing use of GLP-1 RAs for weight loss.
• To highlight the importance of understanding the indications, contraindications, and perioperative management of these medications.
• To discuss the impact of GLP-1 RAs on plastic surgery procedures and patient outcomes.

Main Methods:

• Literature review on the use of GLP-1 RAs in weight management.
• Analysis of the effects of GLP-1 RAs on body composition and aesthetic outcomes.
• Discussion of clinical implications for plastic surgery practice.

Main Results:

• GLP-1 RAs are effectively promoting weight loss, leading to significant morphologic changes.
• There is limited existing literature specifically addressing the implications for plastic surgery.
• The widespread use necessitates awareness among surgeons regarding patient selection and surgical planning.

Conclusions:

• Plastic surgeons must be knowledgeable about GLP-1 RAs to effectively manage patients undergoing or considering aesthetic procedures.
• Understanding perioperative considerations is crucial for optimizing surgical results and patient safety.
• Further research is needed to fully elucidate the long-term effects and optimal management strategies in plastic surgery.